AZ-Dyrk1B-33 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of the DYRK1B kinase, which plays a role in cell cycle regulation and cancer cell survival. By targeting DYRK1B, this compound shows promise in inhibiting the proliferation of certain cancer cells, particularly those resistant to conventional therapies. Research suggests its potential use in treating cancers where DYRK1B overexpression contributes to tumor growth and drug resistance, such as pancreatic cancer and other solid tumors. Additionally, it is being explored for its ability to enhance the efficacy of existing chemotherapeutic agents, offering a synergistic approach to cancer treatment. Further studies are ongoing to evaluate its safety, pharmacokinetics, and potential clinical applications.